Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Brugia malayi | flavodoxin family protein | 0.0189 | 0.7809 | 0.8703 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0197 | 0.8236 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0117 | 0.3975 | 0.3975 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0061 | 0.1028 | 0.1145 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0094 | 0.276 | 0.276 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0095 | 0.2836 | 0.2836 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0189 | 0.7809 | 0.8703 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0061 | 0.1028 | 0.1145 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0072 | 0.162 | 0.1806 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Brugia malayi | FAD binding domain containing protein | 0.0189 | 0.7809 | 0.8703 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0189 | 0.7809 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0211 | 0.8972 | 1 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0211 | 0.8972 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0211 | 0.8972 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0117 | 0.3975 | 0.4431 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0094 | 0.276 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 0.8703 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0189 | 0.7809 | 0.8703 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 0.8703 |
Giardia lamblia | Hypothetical protein | 0.0167 | 0.6669 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0061 | 0.1028 | 0.1028 |
Schistosoma mansoni | voltage-gated potassium channel | 0.023 | 1 | 1 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0061 | 0.1028 | 0.1145 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0211 | 0.8972 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0197 | 0.8236 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0189 | 0.7809 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0189 | 0.7809 | 0.7809 |
Leishmania major | cytochrome P450 reductase, putative | 0.0167 | 0.6669 | 0.8159 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0167 | 0.6669 | 0.5 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0167 | 0.6669 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0183 | 0.7495 | 0.8354 |
Echinococcus granulosus | methionine synthase reductase | 0.0117 | 0.3975 | 0.4431 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0061 | 0.1028 | 0.1145 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0072 | 0.162 | 0.1967 |
Loa Loa (eye worm) | hypothetical protein | 0.0061 | 0.1028 | 0.1145 |
Trypanosoma cruzi | p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0189 | 0.7809 | 0.8703 |
Treponema pallidum | flavodoxin | 0.0072 | 0.162 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0189 | 0.7809 | 0.8703 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0117 | 0.3975 | 0.5 |
Echinococcus granulosus | voltage gated potassium channel | 0.0061 | 0.1028 | 0.1145 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0189 | 0.7809 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0061 | 0.1028 | 0.1028 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0094 | 0.276 | 0.5 |
Echinococcus multilocularis | methionine synthase reductase | 0.0117 | 0.3975 | 0.4431 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0189 | 0.7809 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0072 | 0.162 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0117 | 0.3975 | 0.4431 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0189 | 0.7809 | 1 |
Brugia malayi | flavodoxin family protein | 0.0072 | 0.162 | 0.1806 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0189 | 0.7809 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0189 | 0.7809 | 0.9481 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0167 | 0.6669 | 0.8097 |
Leishmania major | p450 reductase, putative | 0.0189 | 0.7809 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 100 uM | Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method | ChEMBL. | 16879965 |
IC50 (functional) | > 100 uM | Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method | ChEMBL. | 16879965 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.